SCHEDULE: Balyasny Asset Management Discloses Stake in Camp4 Therapeutics

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.07% of Camp4 Therapeutics Corp. common stock as of March 31, 2026.

Summary

• Balyasny Asset Management L.P. (BAM), along with BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively known as the Reporting Persons, have filed a Schedule 13G.
• The filing indicates beneficial ownership of 2,632,437 shares of Camp4 Therapeutics Corp. common stock.
• This ownership represents approximately 5.07% of the class of securities outstanding as of March 4, 2026.
• The shares reported are held by investment management clients Atlas Diversified Master Fund, Ltd (ADMF) and Atlas Private Holdings (Cayman) Ltd. (APHC).
• The Reporting Persons have sole voting power and sole dispositive power over these shares.
• The filing notes that 1,624,523 shares are issuable upon the exercise of warrants, which are subject to a 4.99% exercise blocker to prevent exceeding beneficial ownership limits.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant investment by a known asset manager, but without specific performance data or strategic commentary.

Positives

• Balyasny Asset Management has taken a significant stake, indicating confidence in Camp4 Therapeutics' potential.
• The ownership stake of 5.07% crosses the threshold for beneficial ownership reporting, suggesting a notable investment.
• The Reporting Persons have sole voting and dispositive power, allowing for direct influence over their investment.

Negatives

• The 4.99% exercise blocker on warrants indicates a potential limitation on further increasing their stake without triggering further reporting or regulatory scrutiny.
• The filing does not provide details on the specific investment strategy or rationale behind acquiring this stake.

Risks

• The exercise of warrants is subject to a 4.99% beneficial ownership limitation, which could restrict the ability to fully exercise these warrants if the company's outstanding shares remain constant or decrease.
• Potential for increased scrutiny from regulators or other investors due to the significant ownership stake.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by asset management firms, as seen with Balyasny Asset Management's filing for Camp4 Therapeutics, often signal a belief in the target company's growth prospects or potential for strategic change within the biotechnology sector.

Stakeholder Impact

• Shareholders: May view the investment by Balyasny Asset Management as a positive signal, potentially increasing investor interest.
• Management of Camp4 Therapeutics: May face increased engagement or scrutiny from a significant institutional investor.
• Other Investors: Will be aware of Balyasny's stake, which could influence their own investment decisions.

Next Steps

• The Reporting Persons will continue to hold and manage their investment in Camp4 Therapeutics Corp.
• Further actions may depend on the company's performance and strategic developments.

Key Dates

Recommendation

The filing indicates a significant investment by Balyasny Asset Management, suggesting a positive outlook on Camp4 Therapeutics. However, without further details on the company's performance or strategic plans, a 'hold' recommendation is prudent, allowing for further observation of the investment's impact and the company's trajectory.

Keywords

Camp4 Therapeutics Corp., Schedule 13G, Balyasny Asset Management, Beneficial Ownership, Common Stock, Investment Management, Warrants, SEC Filing